FDA Authorizes Novavax's Covid-19 Vaccine - 14 iulie 2022

U.S. health regulators have authorized the use of Novavax Inc.’s (US.NVAXc) Covid-19 vaccine, providing a new option that works differently than the two leading vaccines, but at a time when overall demand for vaccines and boosters is low.

The Food and Drug Administration said Wednesday that adults 18 years and older may receive Novavax’s vaccine.

The Novavax vaccine, given as two doses three weeks apart, could become available soon if the Centers for Disease Control and Prevention signs off in the coming days.

Novavax scrambled to put together a global manufacturing network for its vaccine, including partnerships with Serum Institute of India Pvt Ltd. and Takeda Pharmaceutical Co. of Japan. Serum Institute of India sells a version of the Novavax vaccine as the brand Covovax, while Novavax uses the brand Nuvaxovid and proposes to use that brand in the U.S.

https://www.wsj.com/articles/fda-authorizes-novavaxs-covid-19-vaccine-11657743595